510(k) K231007
K231007 is an FDA 510(k) premarket notification submitted by Microgenics Corporation for the device "CEDIA Heroin Metabolite (6-AM) Assay". The FDA issued a decision of Substantially Equivalent on September 27, 2023. The device falls under product code DJG (Enzyme Immunoassay, Opiates), a Class II device regulated under 21 CFR 862.3650. Microgenics Corporation has at least 10 other 510(k) clearances on record.
Clearance Details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- September 27, 2023
- Date Received
- April 7, 2023
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device Classification
- Device Name
- Enzyme Immunoassay, Opiates
- Device Class
- Class II
- Regulation Number
- 862.3650
- Review Panel
- TX
- Submission Type